Treatment patterns in patients with prostate cancer and bone metastasis among us community-based urology group practices

Urology

Volumn 80, Issue 2, 2012, Pages 293-298

  Freedland, Stephen J ^a,b,c   Richhariya, Akshara ^d   Wang, Huei ^d   Chung, Karen ^e   Shore, Neal D ^d  

^a Department of Surgery ^*  (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e Carolina Urologic Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER DIAGNOSIS; CANCER SCREENING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; COHORT ANALYSIS; DEMOGRAPHY; FOLLOW UP; HUMAN; MEDICAL AUDIT; PRIORITY JOURNAL; REVIEW; UNITED STATES; UROLOGY;

EID: 84864633303     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.04.007     Document Type: Article

References (15)

1. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 2006 6243s 6249s
2. L. Bubendorf, A. Schöpfer, U. Wagner Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients Hum Pathol 31 2000 578 583
3. N. Sathiakumar, E. Delzell, M.A. Morrisey Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006 Prostate Cancer Prostatic Dis 14 2011 177 183
4. F. Saad, D.M. Gleason, R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
5. E. Chow, P. Hoskin, Y. van der Linden Quality of life and symptom end points in palliative bone metastases trials Clin Oncol (R Coll Radiol) 18 2006 67 69
6. T. Delea, J. McKiernan, J. Brandman Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice J Support Oncol 4 2006 341 347
7. M.J. Lage, B.L. Barber, D.J. Harrison The cost of treating skeletal-related events in patients with prostate cancer Am J Manag Care 14 2008 317 322
8. National Comprehensive Cancer Network NCCN Clinical Practice guidelines in oncology (NCCN Guidelines™) Edition 2010 Prostate Cancer Version 1 2011
9. N.V. Velde, E.Q. Wu, A. Guo The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population Prostate Cancer Prostatic Dis 14 2011 79 84
10. F. Saad, J. Eastham Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer Urology 76 2010 1175 1181
11. H.T. Hatoum, S.J. Lin, A. Guo Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis Curr Med Res Opin 27 2011 55 62
12. H.I. Scher, S. Halabi, I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials Working Group J Clin Oncol 26 2008 1148 1159
13. Zometa® In Zoledronic Acid, Edition 2009 Novartis Pharmaceutical Corp. East Hanover NJ
14. J.E. Mortimer, K. Schulman, J.D. Kohles Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease Clin Breast Cancer 7 2007 682 689
15. A. Oglesby, B. Sherif, D. Odom Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease Community Oncol 6 2009 494 502